Study comparing the effect of pioglitazone in combination with either metformin or sulphonylureas on lipid profile and glycaemic control in patients with type 2 diabetes (ECLA)

Current Medical Research and Opinion

Volumn 27, Issue 2, 2011, Pages 303-313

  Karamanos, B ^a   Thanopoulou, A ^a   Drossinos, V ^b   Charalampidou, E ^b   Sourmeli, S ^b   Archimandritis, A ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b Hellenic Medical Department   (Greece)

Author keywords

Everyday clinical practice; Lipid profile; Pioglitazone

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; FLUINDOSTATIN; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; MEVINOLIN; PIOGLITAZONE; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL;

ADULT; ANEMIA; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; COMPARATIVE STUDY; DIABETIC PATIENT; DIARRHEA; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; EDEMA; FEMALE; FLATULENCE; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPOGLYCEMIA; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 4 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ALGORITHMS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG COMBINATIONS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LIPID METABOLISM; LIPIDS; MALE; METABOLOME; METFORMIN; MIDDLE AGED; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 78651395793     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.542081     Document Type: Article

References (49)

1. Geiss LS, Herman WH, Smith PJ. Mortality in non-insulin-dependent diabetes. In: Diabetes in America, National Institutes of Health, Editorial Board: Maureen Harris et al. 1995:233-57
2. Kuusisto J, Mykkanen L, Pyorala K, et al. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 1994;43:960-7
3. Khaw KT, Wareham N, Bingham S, et al. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 2004;21:413-20
4. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovas-cular and microvascular complications of type 2 diabetes: UKPDS 35 prospective observational study. BMJ 2000;321:405-12
5. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2002;25:S5-S20
6. Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk factor Intervention Trial. Diabetes Care 1993;16:434-44
7. Eberly LE, Cohen JD, Prineas R, et al. Intervention Trial Research Group: Impact of incident diabetes and incident nonfatal cardiovascular disease on 18-year mortality: the Multiple Risk Factor Intervention Trial experience. Diabetes Care 2003;26:848-54
8. Scandinavian simvastatin survival study group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study. Lancet 1994;344:1383-9
9. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels. CARE Trial Circulation 1998;98:2513-19
10. Lewington S, Whitlock G, Clarke R, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths: Prospective Studies Collaboration. Lancet 2007;370:1829-39
11. Castelli WP, Garrison RJ, Wilson PW, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels: The Framingham Study. JAMA 1986;256:2835-8
12. Schaefer EJ, Lamon-Fava S, Ordovas JM, et al. Factors associated with low and elevated plasma high density lipoprotein cholesterol and apolipoprotein A1 levels in the Framingham Offspring Study. J Lipid Res 1994;35:871-82
13. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease: the PROCAM experience. Am J Cardiol 1992;70:733-7
14. Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation 1992;85:37-45
15. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus: randomised controlled trial. Lancet 2005;366:1849-61
16. Standards of Medical Care in Diabetes - 2010. American Diabetes Association. 2010;33:S11-61
17. Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-91
18. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
19. Tzoulaki I, Molokhia M, Curcin V, et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidia-betes drugs: retrospective cohort study using UK general practice research database. BMJ 2009;339:b4731 doi:10.1136/bmj.b4731
20. Desvergue B, Wahli W. Peroxisome proliferation activated receptors: Nuclear control of metabolism. Endocr Rev 1999;20:649-88
21. Sandouk T, Reda D, Hofmann C. The antidiabetic agent pioglitazone increases expression of glucose transporters in 3T3-F442A cells by increasing messenger ribonucleic acid transcript stability. Endocrinol 1993;133:352-9
22. Aronoff S, Rosenblatt S, Braithwaite S, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study: The Pioglitazone 001 Study Group. Diabetes Care 2000;23:1605-11
23. Hanefeld M, Göke B. Combining pioglitazone with sulphonylurea or metformin in the management of type 2 diabetes. Exp Clin Endocrinol Diabetes 2000;108:S256
24. Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazone hydrochloride in combination with metformin therapy improves glycemic control in the treatment of patients with type 2 diabetes mellitus: a randomized placebo-controlled study. Clin Therapeut 2000;22:1395-409
25. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-18
26. Kletzien RF, Clarke SD, Ulrich RG. Enhancement of adipocyte differentiation by an insulin-sensitizing agent. Mol Pharmacol 1992;41:393-8
27. Harris PK, Kletzien RF. Localization of a pioglitazone response element in the adipocyte fatty acid-binding protein gene. Mol Pharmacol 1993;45:439-45
28. Schoonjans K, Onsurbe JP, Lefebvre AM. PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J 1996;15:5336-48
29. European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diabet Med 1999;16:716-30
30. Anonymous. Introduction. Diabetes Care 2009;32:S1-S2
31. Tooth L, Ware R, Bain C, et al. Quality of reporting of observational longitudinal research. Am J Epidemiol 2005;161:280-8
32. Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration;STROBE initiative. PLoS Med 2007;4:e297
33. Des Jarlais DC, Lyles C, Crepaz N. TREND Group: Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: the TREND statement. Am J Public Health 2004;94:361-6
34. Phung OJ, Scholle JM, Talwar M, et al. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypogly-cemia in type 2 diabetes. JAMA 2010;303:1410-18
35. Cambell IW. Long-term glycaemic control with pioglitazone in patients with type 2 diabetes. Int J Clin Pract 2004;58:192-200
36. Liebl A, Mata M, Eschwège E. Evaluation of risk factors for development of complications in type II diabetes in Europe. Diabetologia 2002;45:S23-S28
37. Rosenblatt S, Miskin B, Glazer NB, et al. Pioglitazone 026 Study Group: The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis 2001;12:413-23
38. Kipnes MS, Krosnick A, Rendell MS, et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med 2001;111:10-17
39. Rosenstock J, Einhorn D, Hershon K, et al. Pioglitazone 014 Study Group: Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract 2002;56:251-7
40. Comaschi M, Corsi A, Di Pietro C, et al.;the 'COM06' Study Investigators. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia. Nutr Met and Cardiovasc Dis 2008;18:373-9
41. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease: Four prospective American studies. Circulation 1989;79:8-15
42. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipopro-tein cholesterol. N Engl J Med 1999;341:410-18
43. Robins SJ, Collins D, Wittes JT, et al., VA-HIT Study Group. Veterans Affairs High-Density Lipoprotein Intervention Trial: Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: A randomized controlled trial. JAMA 2001;285:1585-91
44. Dormandy JA, Charbonnel B, Eckland DJ, et al. PROactive investigators: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366: 1279-89
45. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 2002;106:3143
46. Costa J, Borges M, David C, et al. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ 2006;332:1115-24
47. Schöndorf T, Forst T, Hohberg C, et al. The IRIS III study: pioglitazone improves metabolic control and blood pressure in patients with type 2 diabetes without increasing body weight. Diabetes Obes Metab 2007, 9, 132-3
48. Derosa G, D'Angelo A, Ragonesi PD, et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin. Intern Med J 2007;37:79-86 (Pubitemid 46066616)
49. Rodriguez A, Cipres L, Tofe S, et al. Clinical evaluation of combined therapy for type 2 diabetes. Curr Med Res Opin 2010;26:1171-83